Table 2.

Univariate Time-to-event Analyses of Specific Genetic Alterations

Gene	Med. OS (Altered)	Med. OS (Unaltered)	P-value (OS)	Med. PFS (Altered)	Med. PFS (Unaltered)	P-value (PFS)
SMO	6.69	32.36	3.06E-05	2.6	4.5	0.101
CDKN2A/B	6.97	NA	0.000348	4	6.8	0.234
MET	7.1	32.4	0.00247	4.75	4.5	0.427
BRAF	9.07	32.36	0.0034	4.75	4.41	0.462
BRCA1/2	10.8	32.4	0.00522	4.75	4.41	0.541
MSH2/6	6.97	NA	0.00694	2.6	4.5	0.43
ATRX	11.7	32.4	0.0174	4.5	4.41	0.201
DIS3	6.97	32.36	0.0402	4.76	4.5	0.538
MET (amplifications)	9.35	32.36	0.0687	4.76	4.41	0.921
ATM	6.97	32.36	0.0815	2.6	4.76	0.0172
PDGFRA/B	6.97	NA	0.112	2.6	4.76	0.34
MUTYH	32.4	11.7	0.173	10.75	4.41	0.0648
NOTCH2	32.4	11.7	0.18	10.75	4.41	0.12
TSC1/2	6.97	12.54	0.197	2.6	4.5	0.855
TP53	11.7	32.4	0.216	4.5	4.75	0.362
NOTCH1	6.97	12.54	0.332	2.16	4.75	0.338
RB1	12.5	32.4	0.359	2.6	4.5	0.141
TERT	32.4	NA	0.372	2.6	4.75	0.302
MPL	32.4	11.7	0.481	4.76	4.41	0.269
FLT 1/3	NA	32.4	0.505	2.5	4.5	0.36
SOX2/9	NA	12.5	0.546	2.71	4.76	0.00506
ID3	32.4	11.7	0.548	4.76	4.41	0.183
AKT1/2/3	12.5	11.7	0.577	4.75	4.41	0.586
CCNE1	32.4	NA	0.781	4.76	4.5	0.175
ARID1A/B	32.4	11.7	0.794	4.76	4.41	0.264
CIC	32.4	NA	0.893	3.6	4.75	0.62
SDHA/B/C/D	32.4	11.7	0.932	2.63	4.5	0.855
MTOR	32.4	11.7	0.935	4.75	4.41	0.336
JAK1/2/3	12.5	NA	0.966	3.52	4.75	0.867